학술논문
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Document Type
Article
Author
Yang, Jin-Ji; Fang, Jian; Shu, Yong-Qian; Chang, Jian-Hua; Chen, Gong-Yan; He, Jian Xing; Li, Wei; Liu, Xiao-Qing; Yang, Nong; Zhou, Caicun; Huang, Jian An; Frigault, Melanie M.; Hartmaier, Ryan; Ahmed, Ghada F.; Egile, Coumaran; Morgan, Shethah; Verheijen, Remy B.; Mellemgaard, Anders; Yang, Liu; Wu, Yi-Long
Source
Investigational New Drugs; Apr2021, Vol. 39 Issue 2, p477-487, 11p
Subject
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)